Surgery has been reported to be safe with a better surgical outcome compared with the
best supportive care in elderly patients with gastric cancer.[1] The medium OS time and DSS time in OP were 29 and 33 months, respectively, in this study, which was much better than those in BSC.
Bichevet al., "Survival advantage for irinotecan versus
best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)," European Journal of Cancer, vol.
Majority of the patients in our study were stage IV and treated with palliative intent (77%) or received only
best supportive care (16%) due to poor general condition.
they carried out a cost-effectiveness analysis using prospectively collected resource utilization and health utility data for patients in the CO.17 study who received Cetuximab plus
best supportive care (N = 283) or
best supportive care alone (N = 274).
(10) For unresectable advanced or recurrent gastric adenocarcinoma, treatment with systemic chemotherapy improves quality of live (QOL) with marginal survival benefits compared with the
best supportive care. (11-13) Median survival time of patients with advanced adenocarcinoma of the stomach still remains less than one year.
The randomised pivotal trial tested zalutumumab in combination with
best supportive care (BSC) against BSC alone in 286 patients with recurrent or metastatic head/neck cancer who had previously failed at least one course of standard platinum-based chemotherapy.
published a meta-analysis [3] of randomised trials answering the question of utility in terms of improving survival with chemotherapy compared to
best supportive care (a mean average survival benefit of 6 months).
"It has been estimated the costs related to sight impairment for patients treated with Lucentis are around pounds 8,000 cheaper than for patients who receive
best supportive care over a 10-year period.
The phase 3 trial will evaluate approximately 300 previously treated patients with metastatic pancreatic cancer who receive glufosfamide (4500mg/m2) once every three weeks or
best supportive care (BSC).
Also, no evidence has been provided to the institute of the cost-effectiveness of erlotinib for the treatment of patients who would usually receive
best supportive care.
The authors of the guidelines note that patients whose tumors progress without clinical benefit on two consecutive, single-agent regimens are unlikely to benefit from additional chemotherapy, and may be offered the
best supportive care or entry into a clinical trial.
Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus
Best Supportive Care versus Physician's Choice plus
Best Supportive Care.